precise
Winston-Salem, US · Delaware corporation · 1 known investors
Find your way into precise
Sign up to see every warm intro you have to precise
- Paths you didn't know you had: your email and LinkedIn already hold routes to the precise team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Precise Bio is a regenerative medicine company that develops bio-printed tissues and organs using a 4D bio-fabrication platform, initially focused on ophthalmology including a fabricated human cornea program. It serves patients with unmet medical needs that cannot be met with donor tissue, with facilities in North Carolina, USA and Shoham, Israel.
Founders & leadership
AA

Anthony AtalaNamed on SEC filing
AK
Avi KatzNamed on SEC filing
SS

Shay SokerNamed on SEC filing
AB

Aryeh BattNamed on SEC filing
IL
Ilan LiorNamed on SEC filing
YF
Yalon FarhiNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$27.5M disclosed across 2 of 3 rounds · 2018–2024
▶$12MraisedJan 2024 · 8 investors · BiotechnologyRule 506(b)
▶$12MraisedJan 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nathan CaliDirector
- Viko DanaDirector
- Aryeh BattExecutive Officer, Director, Promoter
- Shay SokerDirector, Promoter
- Dirk MuehlhoffDirector
- Ilan LiorDirector
- Ori HadimiExecutive Officer, Director
- Avi KatzDirector
- Anthony AtalaDirector, Promoter
- Offering amount
- $25M
- Amount sold
- $12M
- Minimum investment
- $75K
- Sales commissions
- $75K
- Proceeds to insiders
- $700K
- Placement agents
- Michael Avruch
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.5MraisedFeb 2022 · 70 investors · BiotechnologyRule 506(b)
▶$15.5MraisedFeb 2022 · 70 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony AtalaDirector, Promoter
- Avi KatzExecutive Officer, Director
- Shay SokerDirector, Promoter
- Aryeh BattExecutive Officer, Director, Promoter
- Ilan LiorDirector
- Yalon FarhiDirector
- Offering amount
- $15.5M
- Amount sold
- $15.5M
- Minimum investment
- $15K
- Sales commissions
- $730K
- Finders' fees
- $557K
- Proceeds to insiders
- $700K
- Placement agents
- Nobel Capital
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Precision BioSciencesPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Precision For MedicinePrecision for Medicine is a contract research organization that provides clinical trial management and regulatory support for drug development programs, including oncology, hematology, cell and gene therapy, CAR-T, and radiopharmaceutical trials. It serves pharmaceutical and biotech sponsors running multinational Phase I–IV studies.
Precision NeurosciencePrecision Neuroscience develops a minimally invasive, high-bandwidth brain-computer interface, including its Layer 7 cortical interface, initially aimed at helping people with paralysis control digital devices and robotics using their thoughts. The company works with hospital clinical partners on implanted studies and positions its technology as removable and upgradable without damaging the brain.
PrintBioPrintBio manufactures 3D-printed bioresorbable surgical meshes designed for hernia repair and soft tissue support. The company serves surgeons and hospitals seeking customizable mesh solutions that combine stability and flexibility while reducing infection risk.
Precision Medicine Group, Inc.Precision Medicine Group provides biomarker-driven research and development services and commercialization support for pharmaceutical and life science companies across drug development, manufacturing, and market access.
Companies working in the same space as precise.
Frequently asked questions
- What does precise do?
- Precise Bio is a regenerative medicine company that develops bio-printed tissues and organs using a 4D bio-fabrication platform, initially focused on ophthalmology including a fabricated human cornea program. It serves patients with unmet medical needs that cannot be met with donor tissue, with facilities in North Carolina, USA and Shoham, Israel.
- Who are precise's investors?
- precise's investors include K20 Fund.
- How much funding has precise raised?
- precise has disclosed $27.5M raised across 2 of its 3 known rounds.
- Where is precise headquartered?
- precise is headquartered in Winston-Salem, US.

